A 32-year-old G2P1 woman from Mumbai is diagnosed with gestational diabetes at 26 weeks of gestation on 75 g OGTT (fasting 98 mg/dL, 1-hour 195 mg/dL, 2-hour 168 mg/dL). She is started on medical nutrition therapy and self-monitoring of blood glucose. After 3 weeks of dietary compliance, her fasting glucose remains 105–110 mg/dL and 2-hour postprandial glucose is 145–155 mg/dL (consistently above targets). She is otherwise healthy with no contraindications to medications. What is the most appropriate pharmacological agent to initiate?

Explanation

## Pharmacotherapy for Gestational Diabetes — Drug Selection ### Indications for Pharmacotherapy **Key Point:** Pharmacotherapy is indicated when medical nutrition therapy (MNT) fails to achieve target glucose values after **2 weeks of adherence**. This patient meets criteria: - Fasting glucose: 105–110 mg/dL (target <95 mg/dL) - 2-hour postprandial: 145–155 mg/dL (target <120 mg/dL) - Duration: 3 weeks of dietary compliance ### First-Line Pharmacological Agent: Insulin **High-Yield:** **Insulin is the gold standard and preferred first-line agent for GDM** because: 1. Does not cross the placenta (minimal fetal exposure) 2. Proven efficacy in reducing adverse perinatal outcomes (LGA, neonatal hypoglycemia, preeclampsia) 3. Rapid onset and titration possible 4. No teratogenic effects **Clinical Pearl:** Insulin regimens in GDM typically use: - **NPH (Neutral Protamine Hagedorn):** Intermediate-acting, given once or twice daily - **Rapid-acting analogs (aspart, lispro):** For postprandial hyperglycemia - **Basal-bolus regimen:** If fasting and postprandial control both needed Starting dose: 0.2–0.3 units/kg/day, divided into basal and bolus components. ### Comparison of Oral Agents | Agent | Mechanism | Placental Transfer | Safety in GDM | Role | | --- | --- | --- | --- | --- | | **Metformin** | AMPK activator; ↓ hepatic glucose production | Minimal | Safe; increasingly used as first-line oral agent | Second-line (if insulin declined or as adjunct) | | **Glyburide (Glibenclamide)** | Sulfonylurea; ↑ insulin secretion | Minimal | Acceptable but less effective than insulin | Second-line oral (less preferred than metformin) | | **Acarbose** | α-glucosidase inhibitor; ↓ postprandial glucose | Negligible | Safe but modest efficacy | Rarely used; only for mild postprandial hyperglycemia | ### Why Insulin Over Oral Agents? **Mnemonic: INSULIN FIRST — Why Insulin Beats Oral Agents in GDM:** - **I**mmediate efficacy (rapid glucose lowering) - **N**o placental transfer (fetal safety) - **S**trongest evidence for perinatal outcomes - **U**niversal acceptance in pregnancy - **L**ess teratogenic risk - **I**ndividualized dosing (titration to targets) - **N**o systemic side effects **Warning:** While metformin is increasingly accepted as first-line oral agent (especially in resource-limited settings), insulin remains the **gold standard** and is preferred when oral agents fail or when rapid control is needed. Glyburide is less effective than insulin and metformin for GDM. ### Acarbose: Not Appropriate Here Acarbose is a weak agent for GDM and is reserved only for mild postprandial hyperglycemia in women who refuse insulin or metformin. It does not address fasting hyperglycemia and has limited efficacy. ### Evidence-Based Outcomes **Key Point:** The landmark **Metformin in Gestational Diabetes (MiG) trial** showed that metformin reduced LGA and neonatal hypoglycemia compared to placebo, but **insulin remains superior** for glycemic control and perinatal outcomes in women with moderate-to-severe hyperglycemia (as in this case). --- ### Management Algorithm ```mermaid flowchart TD A[GDM diagnosed on OGTT]:::outcome --> B[Start MNT + SMBG]:::action B --> C{Targets met after 2 weeks?}:::decision C -->|Yes| D[Continue MNT + monitoring]:::action C -->|No| E[Initiate pharmacotherapy]:::action E --> F{Fasting + postprandial hyperglycemia?}:::decision F -->|Yes| G[Insulin monotherapy or combination]:::action F -->|Postprandial only| H[Metformin or insulin]:::action G --> I[Titrate to targets]:::action H --> I I --> J[Delivery planning + neonatal monitoring]:::outcome ```